奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效分析

《奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效分析严（资阳市雁江区人民医院四川资阳641300）【摘要】R的：分析奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效。方法：将我院收治的68例肝硬化合并上消化道出血患者随机分为观察组34例和对照组34例。观察组患者在常规治疗的基础上行奥曲肽联合凝血酶治疗，对照组患者行单纯的奥曲肽治疗。评价2组患者的止血效果，监测患者治疗前后的血液流变学指标，并统计患者治疗后不良反应的发生率。结果：观察组患者止血总有效率为88.23%，对照组为73.53%,2组比较，差异具有统计学意义（P<0.05）。治疗48h后，

2、2组患者门静脉、脾静脉血流量较治疗前下降（P均<0.05），全血粘度高切、低切均较治疗前升高（P均<0.05）。但观察组患者各指标值变化幅度均高于对照组（P均<0.05）。观察组患者恶心、腹胀、心悸及胸闷不良反应总发生率为17.64%，对照组为11.76%，2组比较，差异无统计学意义（P>0.05）。结论：奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床疗效显著，且安全性好，值得临床推广与应用。【关键词】肝硬化合并上消化道出血：奥曲肽：凝血酶【屮图分类号】R657.3+1【文献标识码】B【文章编号】1003-5028（2015）5-0138-02Anal

3、ysistheoctreotidecombinedthrombinclinicalcurativeeffectforthetreatmentofhepatocirrhosiswithuppergastrointestinalbleeding【Abstract】objective:toanalysistheoctreotidecombinedthrombinclinicalcurativeeffectforthetreatmentofhepatocirrhosiswithuppergastrointestinalbleeding.Methods:ourho

4、spital68casesofhepatocirrhosiswithuppergastrointestinalhemorrhagepatientsweredividedintoobservationgroup(34cases))andthecontrolgroup(34cases).Onthebasisofroutinetherapy,observationgroupofpatientstreatedbytheoctreotidecombinedthrombin,thecontrolgrouppatientsweretreatedbythepeptide

5、.Thehemostaticeffectofevaluationof2groupsofpatients,monitoringofpatientsbeforeandaftertreatmentthebloodrheologyindexesandtheincidenceofadversereactionsaftertreatmentinpatientswithstatistics.Results:theobservationgrouppatientsstopbleeding,thetotaleffectiveratewas88.23%inthecontrol

6、groupwas73.53%,thedifferenceoftwogroupshavestatisticalsignificance(P<0.05).48haftertreatment,2groupsofpatientsintheportalandsplenicvenousbloodflowwasdownthewholebloodviscosity(P<0.05),highandlowcutarehigherthanbeforetreatment(P<0.05).Butpatientseachindexchangeinobservati

7、ongroupwerehigherthanthecontrolgroup(P<0.05).Observationgroupofpatientswithnausea,abdominaldistension,palpitationsandchesttightnessadversereactionstothetotalincidencewas17.64%,controlgroupwas11.76%,thecomparisonoftwogroups,therewasnostatisticallysignificantdifference(Pstl30.05

8、).Conclusion:theoctreotidecombinedthromb